A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer
Trial status:Study Complete
Study Identifier:
NT-001
ClinicalTrials.gov Identifier:
EudraCT Identifier:
N/A
Sponsor:
The sponsor of a clinical trial is the company, institution or individual that takes responsibility for initiating, managing, and/or financing a clinical investigation. BioNTech collaborates with other pharmaceutical companies or institutions (collaborators) to develop certain new medicines. In particular cases BioNTech's collaborators are leading specific clinical trials and are acting as sponsors accordingly.
BioNTech US Inc.
Study Complete
Trial details
Medical Condition
Study Drug
Phase
Phase 1
Sex
Female & Male
Age
18+
Estimated Trial Date
Oct 2016 - Feb 2019
Protocol summary
The purpose of this study is to evaluate if the treatment with NEO-PV-01 + adjuvant in combination with nivolumab is safe and useful for patients with certain types of cancer. The study also will investigate if NEO-PV-01 + adjuvant with nivolumab may represent a substantial improvement over other available therapies such as nivolumab alone. All eligible patients will receive NEO-PV-01 + adjuvant and nivolumab while on this trial.
Trial locations
Location
Status
Location
City of Hope
Duarte, California, United States, 91010
Status
Location
UCLA Medical Center
Los Angeles, California, United States, 90095
Status
Location
University of California San Francisco
San Francisco, California, United States, 94143
Status
Location
Massachusetts General Hospital
Boston, Massachusetts, United States, 02114
Status
Location
Dana Farber Cancer Center
Boston, Massachusetts, United States, 02115
Status
Location
Washington University in St. Louis
Saint Louis, Missouri, United States, 63130
Status